Tambiciclib

N/A

Report date: 2026/05/22 20:01:29
NMEFirst In Class

Base Information

Drug NameTambiciclib
Drug Alias NameGF-106GFH-009GFH009SLS-009SLS009 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 9 inhibitors
TargetsCyclin-dependent kinase 9
Therapy Area/IndicationsHematologic NeoplasmsLymphoma, T-Cell, PeripheralLymphoma, Large B-Cell, Diffuse +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesZhejiang Genfleet Therapeutics Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSellas Life Sciences GroupSellas Life Sciences Group IncZhejiang Genfleet Therapeutics Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsLymphoma, T-Cell, PeripheralLymphoma, B-Cell +[6] 
Inactive IndicationsLymphoma, Large B-Cell, Diffuse

Other Information

ATC CodeN/A
Related LinksN/A